Patents by Inventor Walter Piskorski

Walter Piskorski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING (1R, 5S)-1-(NAPHTHALEN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE
    Publication number: 20220347157
    Abstract: Provided are pharmaceutical compositions comprising (1R,55)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form. The compositions are formulated for providing a sustained release of enantiomerically pure (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.O)]hexane. The compositions are substantially free of the other (—) enantiomer of the compound.
    Type: Application
    Filed: March 10, 2022
    Publication date: November 3, 2022
    Inventors: Anthony McKinney, Brain McMillan, Mattew Greene, Walter Piskorski
  • Crystalline compounds
    Patent number: 11299458
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: April 12, 2022
    Assignee: OTSUKA AMERICA PHARMACEUTICAL, INC.
    Inventors: Anthony Alexander McKinney, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
  • CRYSTALLINE COMPOUNDS
    Publication number: 20210198198
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Application
    Filed: August 14, 2020
    Publication date: July 1, 2021
    Inventors: Anthony Alexander MCKINNEY, Franklin BYMASTER, Walter PISKORSKI, Fred J. FLEITZ, Yonglai YANG, David A. ENGERS, Valeriya SMOLENSKAYA, Venkat KUSUKUNTLA
  • PREPARATION AND USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS
    Publication number: 20210161863
    Abstract: The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable active salts, polymorphs, glycosylated derivatives, metabolites, solvates, hydrates, and/or prodrugs of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and their use alone or in combination with additional psychotherapeutic compositions in the treatment of conditions affected by monoamine neurotransmitters, including treatment of refractory individuals.
    Type: Application
    Filed: September 30, 2020
    Publication date: June 3, 2021
    Inventors: Anthony Alexander McKinney, Frank Bymaster, Walter Piskorski
  • Crystalline compounds
    Patent number: 10800740
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: October 13, 2020
    Assignee: OTSUKA AMERICA PHARMACEUTICAL, INC.
    Inventors: Anthony Alexander McKinney, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
  • CRYSTALLINE COMPOUNDS
    Publication number: 20200039934
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Application
    Filed: March 11, 2019
    Publication date: February 6, 2020
    Inventors: Anthony Alexander MCKINNEY, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
  • PREPARATION AND USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS
    Publication number: 20190358199
    Abstract: The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable active salts, polymorphs, glycosylated derivatives, metabolites, solvates, hydrates, and/or prodrugs of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and their use alone or in combination with additional psychotherapeutic compositions in the treatment of conditions affected by monoamine neurotransmitters, including treatment of refractory individuals.
    Type: Application
    Filed: December 28, 2018
    Publication date: November 28, 2019
    Inventors: Anthony Alexander McKinney, Frank Bymaster, Walter Piskorski
  • Crystalline compounds
    Patent number: 10280141
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: May 7, 2019
    Assignee: OTSUKA AMERICA PHARMACEUTICAL, INC.
    Inventors: Anthony Alexander McKinney, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
  • PREPARATION AND USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS
    Publication number: 20180256542
    Abstract: The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable active salts, polymorphs, glycosylated derivatives, metabolites, solvates, hydrates, and/or prodrugs of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and their use alone or in combination with additional psychotherapeutic compositions in the treatment of conditions affected by monoamine neurotransmitters, including treatment of refractory individuals.
    Type: Application
    Filed: October 13, 2017
    Publication date: September 13, 2018
    Inventors: Anthony Alexander McKinney, Frank Bymaster, Walter Piskorski
  • CRYSTALLINE COMPOUNDS
    Publication number: 20180194726
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Application
    Filed: November 21, 2017
    Publication date: July 12, 2018
    Inventors: Anthony Alexander MCKINNEY, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
  • Crystalline compounds
    Patent number: 9856217
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: January 2, 2018
    Assignee: NEUROVANCE, INC.
    Inventors: Anthony Alexander McKinney, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
  • Methods of treating fragile X associated disorders, ADHD, and autism spectrum disorder
    Patent number: 9839627
    Abstract: Provided are novel methods comprising administering a therapeutically effective amount of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, to a patient in need thereof.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: December 12, 2017
    Assignee: NEUROVANCE, INC.
    Inventors: Anthony McKinney, Frank Gentile, Timothy Hsu, Franklin Bymaster, Walter Piskorski, Richard Welter
  • CRYSTALLINE COMPOUNDS
    Publication number: 20170334850
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Application
    Filed: June 1, 2017
    Publication date: November 23, 2017
    Inventors: Anthony Alexander MCKINNEY, Franklin BYMASTER, Walter PISKORSKI, Fred J. FLEITZ, Yonglai YANG, David A. ENGERS, Valeriya SMOLENSKAYA, Venkat KUSUKUNTLA
  • Crystalline compounds
    Patent number: 9708261
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: July 18, 2017
    Assignee: NEUROVANCE, INC.
    Inventors: Anthony Alexander McKinney, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
  • CRYSTALLINE COMPOUNDS
    Publication number: 20160368871
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Application
    Filed: June 17, 2016
    Publication date: December 22, 2016
    Inventors: Anthony Alexander MCKINNEY, Franklin BYMASTER, Walter PISKORSKI, Fred J. FLEITZ, Yonglai YANG, David A. ENGERS, Valeriya SMOLENSKAYA
  • NOVEL METHODS
    Publication number: 20160303076
    Abstract: Provided are novel methods comprising administering a therapeutically effective amount of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, to a patient in need thereof.
    Type: Application
    Filed: December 9, 2014
    Publication date: October 20, 2016
    Applicant: Neurovance, Inc.
    Inventors: Anthony MCKINNEY, Frank GENTILE, Timothy HSU, Franklin BYMASTER, Walter PISKORSKI, Richard WELTER
  • NOVEL COMPOSITIONS
    Publication number: 20160303077
    Abstract: Provided are pharmaceutical compositions comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form. The compositions are formulated for providing a sustained release of enantiomerically pure (1R,5S)-1-(naphthalene-2-yl)-3-azabicyclo[3.1.0]hexane. The compositions are substantially free of the other (?) enantiomer of the compound.
    Type: Application
    Filed: December 9, 2014
    Publication date: October 20, 2016
    Inventors: Anthony MCKINNEY, Brian MCMILLAN, Matthew GREENE, Walter PISKORSKI
  • PREPARATION AND USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS
    Publication number: 20140039029
    Abstract: The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable active salts, polymorphs, glycosylated derivatives, metabolites, solvates, hydrates, and/or prodrugs of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and their use alone or in combination with additional psychotherapeutic compositions in the treatment of conditions affected by monoamine neurotransmitters, including treatment of refractory individuals.
    Type: Application
    Filed: June 20, 2013
    Publication date: February 6, 2014
    Inventors: Anthony Alexander McKinney, Frank Bymaster, Walter Piskorski
  • Preparation and Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane In The Treatment of Conditions Affected by Monoamine Neurotransmitters
    Publication number: 20120258994
    Abstract: The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable active salts, polymorphs, glycosylated derivatives, metabolites, solvates, hydrates, and/or prodrugs of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and their use alone or in combination with additional psychotherapeutic compositions in the treatment of conditions affected by monoamine neurotransmitters, including treatment of refractory individuals.
    Type: Application
    Filed: December 2, 2011
    Publication date: October 11, 2012
    Inventors: Anthony Alexander McKINNEY, Frank Bymaster, Walter Piskorski
  • Multiple-dose dispenser for dry powder inhalers
    Patent number: 5794613
    Abstract: A multiple-dose dispenser for use with dry powder inhalers is disclosed. The dispenser has a two-piece construction and includes a plurality of individual, hermetically sealed chambers for retaining unit doses of a dry powder for inhalation. Also disclosed is a method for producing the multiple-dose dispenser.
    Type: Grant
    Filed: January 9, 1997
    Date of Patent: August 18, 1998
    Assignee: Sepracor, Inc.
    Inventor: Walter Piskorski